Inna A. Larkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Inna A. Larkova has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Vera Afanas’eVna Revyakina
Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation
15 shared publications - Elena Dmitrievna Kuvshinova
Federal Research Centre of Nutrition, Biotechnology, and Food Safety, 109240, Moscow, Russian Federation
7 shared publications - Valeriy A. Mukhortykh
Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation
7 shared publications - Elena V. Stezhkina
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University named after Academician I. P. Pavlov” of the Ministry of Health of the Russian Federation
3 shared publications - Natalia Begievna Migacheva
Samara State Medical University
3 shared publications - Olga Valerievna Trusova
Federal State Budgetary Educational Institution of Higher Education First St. Petersburg State Medical University named after Academician I.P. Pavlov of the Ministry of Health of the Russian Federation / Pavlov University
3 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Allergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Open AccessAllergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- 25 December 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (6)
The role of polyunsaturated fatty acids in the development of allergic diseases
Introduction. The steady increase in the prevalence and severity of allergic diseases worldwide necessitates the search for new pathogenetic mechanisms and preventive strategies. In addition to genetic predisposition, environmental factors, particularly the nature of nutrition during critical periods of early ontogenesis, have a significant impact on the development of the immune response and the risk for atopy. Polyunsaturated fatty acids (PUFAs) play a central role in this process, and the imbalance between the consumption of pro-inflammatory omega-6 and anti-inflammatory ω-3 PUFAs is considered a key factor in the epidemiology of allergic diseases. The aim. To systematize current data on the role and mechanisms of the effect of long-chain PUFA on the risk of development and course of allergic diseases, as well as to assess the potential for their use in prevention and therapy, taking into account genetic features of metabolism.Materials and methods. The analysis of data from epidemiological, observational, and intervention studies, as well as systematic reviews, devoted to the study of the relationship between the consumption of PUFAs (both with food and in the form of supplements) during pregnancy, lactation, and early childhood with markers of immune response and clinical outcomes of allergic diseases. Special attention is paid to the role of polymorphisms of genes of the FADS cluster (FADS1, FADS2), encoding desaturase enzymes, in the modulation of the effects of PUFAs.Results. The biological effects of ω-6 (arachidonic acid, ArA) and ω-3 (eicosapentaenoic acid, EPA and docosahexaenoic acid, DHA) PUFA were established to be opposite. ARA metabolites (prostaglandins, leukotrienes) provoke and support allergic inflammation, promote the polarization of the Th2-type immune response and IgE synthesis. On the contrary, ω-3 PUFAs compete with arcs for enzymes, suppressing the synthesis of pro-inflammatory eicosanoids and promoting the formation of specialized resolving mediators (SRM) that resolve inflammation and promote the formation of immune tolerance. Taking ω-3 PUFA supplements during pregnancy and lactation has been shown to be associated with a reduced risk of atopic dermatitis, sensitization to food allergens (especially egg white) and bronchial asthma in children, and the effects can persist for many years. The enrichment of infant formula with PUFA brings their immunomodulatory properties closer to those of breast milk. The effectiveness of PUFA interventions significantly depends on the genetic profile. Carriers of minor alleles of polymorphisms of the FADS genes are characterized by reduced desaturase activity, which leads to lower baseline concentrations of PUFA (especially ARA) and, as a result, to a greater susceptibility to the positive effects of supplementation of ω-3 PUFA and to a potentially lower risk of developing allergies mediated by reduced synthesis of proinflammatory mediators. The “genotype-diet” interaction is a critical factor: dietary interventions (for example, breastfeeding, increased consumption of fish) demonstrate the most pronounced protective effect in carriers of certain genotypes. At the same time, the data from individual studies are contradictory, which may be due to differences in research design, dosages, initial nutritional status of participants and their genetic background.Conclusion. Long-chain PUFA play a fundamental role in the modulation of immune processes underlying the pathogenesis of allergic diseases. ω-3 PUFA supplementation during the perinatal period and early childhood demonstrates significant potential for the primary prevention of atopy. However, further large-scale prospective studies are required to develop personalized recommendations, taking into account the genetic characteristics of PUFA metabolism (primarily, the FADS cluster polymorphisms), which will allow identifying target populations, optimal doses, timing, and duration of interventions to maximize their clinical effectiveness.Contribution: Mukhortykh V.A., Larkova I.A. — creation of the concept, construction of sections of the work; Mukhortykh V.A., Larkova I.A., Tarmaeva N.A. — work with literature sources, analysis and generalization of the data obtained, writing the text; Revyakina V.A. — editing the text. All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.Acknowledgment. The research work on the preparation of the manuscript was carried out using funds from a subsidy for the implementation of a state assignment within the framework of the Fundamental Scientific Research Program (FGMF-2025-0003).Conflict of interest. The authors declare no conflict of interest.Received: November 06, 2025Accepted: November 27, 2025Published: December 25, 2025
- 25 December 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (6)
The role of polyunsaturated fatty acids in the development of allergic diseases
Introduction. The steady increase in the prevalence and severity of allergic diseases worldwide necessitates the search for new pathogenetic mechanisms and preventive strategies. In addition to genetic predisposition, environmental factors, particularly the nature of nutrition during critical periods of early ontogenesis, have a significant impact on the development of the immune response and the risk for atopy. Polyunsaturated fatty acids (PUFAs) play a central role in this process, and the imbalance between the consumption of pro-inflammatory omega-6 and anti-inflammatory ω-3 PUFAs is considered a key factor in the epidemiology of allergic diseases. The aim. To systematize current data on the role and mechanisms of the effect of long-chain PUFA on the risk of development and course of allergic diseases, as well as to assess the potential for their use in prevention and therapy, taking into account genetic features of metabolism.Materials and methods. The analysis of data from epidemiological, observational, and intervention studies, as well as systematic reviews, devoted to the study of the relationship between the consumption of PUFAs (both with food and in the form of supplements) during pregnancy, lactation, and early childhood with markers of immune response and clinical outcomes of allergic diseases. Special attention is paid to the role of polymorphisms of genes of the FADS cluster (FADS1, FADS2), encoding desaturase enzymes, in the modulation of the effects of PUFAs.Results. The biological effects of ω-6 (arachidonic acid, ArA) and ω-3 (eicosapentaenoic acid, EPA and docosahexaenoic acid, DHA) PUFA were established to be opposite. ARA metabolites (prostaglandins, leukotrienes) provoke and support allergic inflammation, promote the polarization of the Th2-type immune response and IgE synthesis. On the contrary, ω-3 PUFAs compete with arcs for enzymes, suppressing the synthesis of pro-inflammatory eicosanoids and promoting the formation of specialized resolving mediators (SRM) that resolve inflammation and promote the formation of immune tolerance. Taking ω-3 PUFA supplements during pregnancy and lactation has been shown to be associated with a reduced risk of atopic dermatitis, sensitization to food allergens (especially egg white) and bronchial asthma in children, and the effects can persist for many years. The enrichment of infant formula with PUFA brings their immunomodulatory properties closer to those of breast milk. The effectiveness of PUFA interventions significantly depends on the genetic profile. Carriers of minor alleles of polymorphisms of the FADS genes are characterized by reduced desaturase activity, which leads to lower baseline concentrations of PUFA (especially ARA) and, as a result, to a greater susceptibility to the positive effects of supplementation of ω-3 PUFA and to a potentially lower risk of developing allergies mediated by reduced synthesis of proinflammatory mediators. The “genotype-diet” interaction is a critical factor: dietary interventions (for example, breastfeeding, increased consumption of fish) demonstrate the most pronounced protective effect in carriers of certain genotypes. At the same time, the data from individual studies are contradictory, which may be due to differences in research design, dosages, initial nutritional status of participants and their genetic background.Conclusion. Long-chain PUFA play a fundamental role in the modulation of immune processes underlying the pathogenesis of allergic diseases. ω-3 PUFA supplementation during the perinatal period and early childhood demonstrates significant potential for the primary prevention of atopy. However, further large-scale prospective studies are required to develop personalized recommendations, taking into account the genetic characteristics of PUFA metabolism (primarily, the FADS cluster polymorphisms), which will allow identifying target populations, optimal doses, timing, and duration of interventions to maximize their clinical effectiveness.Contribution: Mukhortykh V.A., Larkova I.A. — creation of the concept, construction of sections of the work; Mukhortykh V.A., Larkova I.A., Tarmaeva N.A. — work with literature sources, analysis and generalization of the data obtained, writing the text; Revyakina V.A. — editing the text. All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.Acknowledgment. The research work on the preparation of the manuscript was carried out using funds from a subsidy for the implementation of a state assignment within the framework of the Fundamental Scientific Research Program (FGMF-2025-0003).Conflict of interest. The authors declare no conflict of interest.Received: November 06, 2025Accepted: November 27, 2025Published: December 25, 2025
- 25 December 2025
- Published by Bionika Media in Pharmateca
- Vol. 10_2025
Treatment of atopic dermatitis in pediatric practice: challenges and solutions
- 25 December 2025
- Published by Bionika Media in Pharmateca
- Vol. 10_2025
Treatment of atopic dermatitis in pediatric practice: challenges and solutions
- Open Access
- 28 February 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (1) , 74-78
Achievements and prospects in the prevention of food allergies
The review presents achievements and prospects in the prevention of food allergies (FA). The incidence of FA has increased worldwide, and this has determined the need to change approaches to the primary prevention of FA, which for a long time relied on elimination strategies in the diet of not only children, but also pregnant and lactating women. The aim of the review is to determine the advantages of early introduction of highly allergenic foods as complementary foods for FA prevention. Literature was searched in the following databases: PubMed, Embase, Cochrane Library, Google. For children at high risk of developing FA, there is convincing evidence of the benefits of early administration of allergenic foods, in particular peanuts and eggs. It is believed that in such cases, not only should these products not be delayed, but they should be administered around the age of 4–6 months to minimize the risk of developing FA. All current guidelines recommend this approach regardless of the risk of developing FA. Conclusion. Taking into account the trends towards the early introduction of allergenic products as a prevention of FA, it can be argued that a significant transition has been made from an elimination strategy to a strategy for the formation of tolerance to food allergens.
- 28 February 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (1) , 74-78
Open AccessAchievements and prospects in the prevention of food allergies
The review presents achievements and prospects in the prevention of food allergies (FA). The incidence of FA has increased worldwide, and this has determined the need to change approaches to the primary prevention of FA, which for a long time relied on elimination strategies in the diet of not only children, but also pregnant and lactating women. The aim of the review is to determine the advantages of early introduction of highly allergenic foods as complementary foods for FA prevention. Literature was searched in the following databases: PubMed, Embase, Cochrane Library, Google. For children at high risk of developing FA, there is convincing evidence of the benefits of early administration of allergenic foods, in particular peanuts and eggs. It is believed that in such cases, not only should these products not be delayed, but they should be administered around the age of 4–6 months to minimize the risk of developing FA. All current guidelines recommend this approach regardless of the risk of developing FA. Conclusion. Taking into account the trends towards the early introduction of allergenic products as a prevention of FA, it can be argued that a significant transition has been made from an elimination strategy to a strategy for the formation of tolerance to food allergens.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 94 (4) , 68-75
Evaluation of biomarkers of intestinal permeability and inflammation in food allergies
Оценка биомаркеров проницаемости кишечника и воспаления при пищевой аллергии
- 1 January 2025
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 94 (4) , 68-75
Open AccessEvaluation of biomarkers of intestinal permeability and inflammation in food allergies
Оценка биомаркеров проницаемости кишечника и воспаления при пищевой аллергии
- Open Access
- 7 January 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 4,p. 5-30
Allergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)
The Document contains fundamental provisions regarding allergen specific immunotherapy in children.International clinical recommendations on the methodology were used, adapted for use in real practice.In the absence of international recommendations, the authors present the consensus opinion of the project participants, based on data from clinical studies in this area.At the moment, we bring to your attention a position paper on allergen specific immunotherapy in children, created by experts from the Association of Pediatric Allergologists and Immunologists of Russia (APAIR) based on the 2021 consensus document, with the necessary data updates.
- 7 January 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 4,p. 5-30
Open AccessAllergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)
The Document contains fundamental provisions regarding allergen specific immunotherapy in children.International clinical recommendations on the methodology were used, adapted for use in real practice.In the absence of international recommendations, the authors present the consensus opinion of the project participants, based on data from clinical studies in this area.At the moment, we bring to your attention a position paper on allergen specific immunotherapy in children, created by experts from the Association of Pediatric Allergologists and Immunologists of Russia (APAIR) based on the 2021 consensus document, with the necessary data updates.
- 1 January 2024
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 22 (3)
Food allergy. Innovative methods of diagnosis and therapy
This review presents literature data on the prevalence of food allergy and food intolerance, clinical manifestations of IgE- and non-IgE-mediated immune reactions, as well as the results of our own research on the identification of causative food allergens using molecular diagnostics. Current approaches to diagnosis, diet therapy, and innovations in pharmacotherapy are described. Key words: food allergy, food intolerance, children, molecular diagnostics, diet therapy, biopharmaceuticals
- 1 January 2024
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 22 (3)
Food allergy. Innovative methods of diagnosis and therapy
This review presents literature data on the prevalence of food allergy and food intolerance, clinical manifestations of IgE- and non-IgE-mediated immune reactions, as well as the results of our own research on the identification of causative food allergens using molecular diagnostics. Current approaches to diagnosis, diet therapy, and innovations in pharmacotherapy are described. Key words: food allergy, food intolerance, children, molecular diagnostics, diet therapy, biopharmaceuticals
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 93 (4) , 104-111
Assessment of tolerance of a new product (gluten-free grain snack) in children with food allergy to gluten
Оценка переносимости нового продукта (безглютенового зернового снека) у детей с пищевой аллергией к глютену
- 1 January 2024
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 93 (4) , 104-111
Open AccessAssessment of tolerance of a new product (gluten-free grain snack) in children with food allergy to gluten
Оценка переносимости нового продукта (безглютенового зернового снека) у детей с пищевой аллергией к глютену
- Open Access
- 31 October 2023
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 26 (5) , 368-375
Food allergy to cow’s milk proteins and meat
Introduction. Cow’s milk and dairy products are important sources of high-quality animal proteins, calcium, vitamins, and minerals. They are widely used in the diet of preschool and school-age children and contribute to the normal development and resilience of children against the effects of adverse external factors. However, cow’s milk can cause serious allergic reactions in children, even leading to anaphylaxis. Allergy to cow’s milk proteins is one of the common allergic reactions among preschool-age children. Through conducted research, patterns of the natural course of milk allergy over time have been established. In most cases, by the age of 5 years, children develop tolerance to cow’s milk proteins. However, some school-age children may retain heightened sensitivity to them. Sustaining such prolonged milk allergy in a school-age child requires identifying the cause and conducting in-depth examinations for each specific patient. In such cases, valuable information about elevated sensitivity to whole cow’s milk protein and its components is provided by molecular (component-based) diagnostics. This enables the identification of causally significant components (α-lactalbumin, β-lactoglobulin, bovine serum albumin) of milk protein for the purpose of rational diet therapy, considering cross-reactions with beef meat. The presented article summarizes and systematizes literary and proprietary data on allergy to cow’s milk proteins and its components, as well as to beef meat. Understanding the characteristics of allergy to cow’s milk proteins and its components, cross-reacting with beef, will help avoid serious consequences of irrational elimination diets.
- 31 October 2023
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 26 (5) , 368-375
Open AccessFood allergy to cow’s milk proteins and meat
Introduction. Cow’s milk and dairy products are important sources of high-quality animal proteins, calcium, vitamins, and minerals. They are widely used in the diet of preschool and school-age children and contribute to the normal development and resilience of children against the effects of adverse external factors. However, cow’s milk can cause serious allergic reactions in children, even leading to anaphylaxis. Allergy to cow’s milk proteins is one of the common allergic reactions among preschool-age children. Through conducted research, patterns of the natural course of milk allergy over time have been established. In most cases, by the age of 5 years, children develop tolerance to cow’s milk proteins. However, some school-age children may retain heightened sensitivity to them. Sustaining such prolonged milk allergy in a school-age child requires identifying the cause and conducting in-depth examinations for each specific patient. In such cases, valuable information about elevated sensitivity to whole cow’s milk protein and its components is provided by molecular (component-based) diagnostics. This enables the identification of causally significant components (α-lactalbumin, β-lactoglobulin, bovine serum albumin) of milk protein for the purpose of rational diet therapy, considering cross-reactions with beef meat. The presented article summarizes and systematizes literary and proprietary data on allergy to cow’s milk proteins and its components, as well as to beef meat. Understanding the characteristics of allergy to cow’s milk proteins and its components, cross-reacting with beef, will help avoid serious consequences of irrational elimination diets.
- Open Access
- 9 October 2023
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3,p. 34-57
The results of a survey of Russian doctors in order to identify the compliance of the management of children with chronic urticaria with clinical recommendations
Introduction. Primary observation of children with (CU) in Russia is performed by pediatricians, dermatologists, and algologists. It is unclear how clinical guidelines are used in a heterogeneous group of specialists.Materials and methods. Online survey of pediatricians, allergists, and dermatologists (n = 304) in the Russian Federation using a questionnaire, from 5 blocks of questions related to etiology, diagnosis, and therapy. 316 physicians with a median experience of 10 [5; 20] years were included in the questionnaire.Results. 83.3 % of respondents observed no more than 2 children with CU per month. Self-education to expand knowledge (video lectures, special literature) was indicated by 72.6 % of participants. The clinical guidelines used by physicians were documents of pediatric and allergy associations of Russia (77.3 and 55.9 %, respectively), international guides were used by 27 % of respondents.The most frequent deviations from the recommended algorithm were the prescription of biochemical blood tests (64.9 %), ultrasound examination of organs (56.9 %), consultations of specialists without indications: gastroenterologist (48.2 %), infectious disease specialist (31.8 %), rheumatologist (27.1 %). The autologous serum test in children is not used by 87.2 % of physicians for various reasons.During allergy testing, respondents recommend: the concentration of total IgE in serum (63.9 %), the number of eosinophils in the blood (61.2 %). The importance of determining specific IgE was indicated by no more than one third of the respondents. Skin tests during remission period were supported by 59.1 % of all physicians, who considered allergologic examination to be necessary. Diet: 18.6 % of respondents do not recommend a special diet for children; 27.7 % exclude from the diet foods to which sensitization is detected, the rest recommend an nonspecific elimination diet.Antihistamines of 2nd generation (AG II) are the most used in clinical practice (86.5 %). Physicians named cetirizine (25.7 %) and levocetirizine (19.7 %) as the drugs of choice up to 12 years of age. The need to double the dose of AG II in the absence of response to the standard dose was supported by 59.5 % of physicians. The other physicians preferred a change of AG II molecule in the standard dose. Experience with the use of omalizumab was reported by 20 % of specialists, with 76.3 % understanding the significance and willingness to use biologic therapy. If omalizumab is ineffective, 44.1 % of physicians consider glucocorticosteroids to be the drug of choice; 38.8 % — cyclosporine A. About one third of physicians use alternative therapies not considered in the clinical guidelines.Conclusion. A significant number of physicians do not use recommendations based on evidence-based studies in real practice. AG II are the basis of CU therapy in children in all age groups.
- 9 October 2023
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3,p. 34-57
Open AccessThe results of a survey of Russian doctors in order to identify the compliance of the management of children with chronic urticaria with clinical recommendations
Introduction. Primary observation of children with (CU) in Russia is performed by pediatricians, dermatologists, and algologists. It is unclear how clinical guidelines are used in a heterogeneous group of specialists.Materials and methods. Online survey of pediatricians, allergists, and dermatologists (n = 304) in the Russian Federation using a questionnaire, from 5 blocks of questions related to etiology, diagnosis, and therapy. 316 physicians with a median experience of 10 [5; 20] years were included in the questionnaire.Results. 83.3 % of respondents observed no more than 2 children with CU per month. Self-education to expand knowledge (video lectures, special literature) was indicated by 72.6 % of participants. The clinical guidelines used by physicians were documents of pediatric and allergy associations of Russia (77.3 and 55.9 %, respectively), international guides were used by 27 % of respondents.The most frequent deviations from the recommended algorithm were the prescription of biochemical blood tests (64.9 %), ultrasound examination of organs (56.9 %), consultations of specialists without indications: gastroenterologist (48.2 %), infectious disease specialist (31.8 %), rheumatologist (27.1 %). The autologous serum test in children is not used by 87.2 % of physicians for various reasons.During allergy testing, respondents recommend: the concentration of total IgE in serum (63.9 %), the number of eosinophils in the blood (61.2 %). The importance of determining specific IgE was indicated by no more than one third of the respondents. Skin tests during remission period were supported by 59.1 % of all physicians, who considered allergologic examination to be necessary. Diet: 18.6 % of respondents do not recommend a special diet for children; 27.7 % exclude from the diet foods to which sensitization is detected, the rest recommend an nonspecific elimination diet.Antihistamines of 2nd generation (AG II) are the most used in clinical practice (86.5 %). Physicians named cetirizine (25.7 %) and levocetirizine (19.7 %) as the drugs of choice up to 12 years of age. The need to double the dose of AG II in the absence of response to the standard dose was supported by 59.5 % of physicians. The other physicians preferred a change of AG II molecule in the standard dose. Experience with the use of omalizumab was reported by 20 % of specialists, with 76.3 % understanding the significance and willingness to use biologic therapy. If omalizumab is ineffective, 44.1 % of physicians consider glucocorticosteroids to be the drug of choice; 38.8 % — cyclosporine A. About one third of physicians use alternative therapies not considered in the clinical guidelines.Conclusion. A significant number of physicians do not use recommendations based on evidence-based studies in real practice. AG II are the basis of CU therapy in children in all age groups.